Spots Global Cancer Trial Database for Use Of Oral Itraconazole In Patients With Locally Limited Basocellular Carcinoma Of Skin.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Use Of Oral Itraconazole In Patients With Locally Limited Basocellular Carcinoma Of Skin.

Official Title: Evaluation Of The Treatment With Oral Itraconazole In Patients With Basocellular Carcinoma Of Skin, Locally Limited Disease.

Study ID: NCT03972748

Conditions

Basal Cell Carcinoma

Hedgehog Pathway

Interventions

Itraconazole 200 mg

Study Description

Brief Summary: Patients with localized basocellular carcinoma of the skin, will receive oral Itraconazole, 200 mg twice daily, for 60 days, prior to curative intent surgery.

Detailed Description: Patients with localized basocellular carcinoma of the skin, will receive oral Itraconazole, 200 mg once daily, for 60 days, before surgery with curative intent. Tumor area regression will be measured through dermatologic evaluation and photographic documentation on baseline and at the end of the 60 day treatment period. The activity of the Hedgehog pathway will be measured on tissue samples obtained at the time of diagnosis and at the time of curative intent surgery, through the measuring of the Ki67 index.